- Administration Mode
Hepatofit Forte is useful for persons with high levels of transaminases.
Long-term administration does not cause side effects.
Hepatofit forte improves the quality of life in patients through its effects: fights asthenia, eliminates fatigue, stimulates digestion, regulates biliary function, increases appetite.
The evaluation of the product’s efficacy was made in collaboration with gastroenterologists in some university clinics. After 3 months of administration (1 capsule x 3/day) transaminases decreased by at least 70% of the exceeded normal values.
Vegetable ingredients also ensure a rapid absorption. They were dosed to obtain a mutual potentiation effect.
Product type: Food supplement
Net weight: 36,5 g
Storage: Store in a dry place, at room temperature
-milk thistle fruits extract (Silybi mariani fructus) standardised in min. 85% silymarin 150 mg
-five-flavor berry (Schisandra chinensis) extract standardised in min. 1% schisandrină 144 mg
-artichoke leaves extract (Cynarae folium) standardised in min. 2,5% cynarin
-greater celandine extract (Chelidonii herba) standardised in min. 2% chelidonine 66 mg
-dandelion root extract (Taraxaci radix) standardised in min. 5% polyphenols 24 mg
-yellow sweet clover extract (Meliloti herba) standardised in min. 5% polyphenols 24 mg.
For hepatoprotection: 1 capsule 3 times a day, before a meal.
For hepatic regeneration: 2 capsules de 3 times a day, before a meal, for at least 3 months.
Maintenance treatment: 1 capsule 3 times a day, before a meal, for long term.
Not recommended in case of biliary obstruction, for children under 6 years and in case of hypersensitivity to any of the product’s ingredients.
PREGNANCY AND BREASTFEEDING:
Not recommended for pregnant women due to possible effects of stimulating uterine contractions. Not recommended for breastfeeding mothers due to the fact that the active substances pass into breast milk and may change its taste.
SIDE EFFECTS AND INTERACTIONS:
This product can be taken together with other drugs. No side effects were reported at the recommended doses.